Key Financial Figures (Standalone)

  • Total Income: ₹66.00 crore (FY26) vs ₹71.31 crore (FY25)
  • Revenue from Operations: ₹64.76 crore, decreased by 7.61% from ₹70.10 crore in FY25
  • Profit Before Tax: ₹9.23 crore vs ₹10.36 crore in FY25
  • Profit After Tax: ₹6.92 crore vs ₹8.10 crore in FY25
  • Earnings Per Share (Basic): ₹5.67 vs ₹6.89 in FY25
  • Total Assets: ₹78.43 crore as of 31st March 2026
  • Share Capital: ₹12.28 crore (1,22,84,300 equity shares of ₹10 each)

Key Financial Figures (Consolidated)

  • Revenue from Operations: ₹68.67 crore
  • Profit After Tax: ₹6.69 crore
  • Earnings Per Share (Basic): ₹5.49

Capital Structure Changes

  • Converted balance 4,02,606 warrants into equity shares upon receipt of balance application money
  • Total 6,00,000 warrants originally allotted on 5th February 2024 fully converted into equity shares
  • Issued capital increased to ₹12.28 crore from ₹11.88 crore

Subsidiaries and Joint Ventures

  • SPL Infusion Private Limited: 60% subsidiary, incorporated on 26th February 2024
  • Share capital: ₹1.55 crore
  • Reserves and surplus: ₹4.73 crore
  • Total assets: ₹46.60 crore
  • Turnover: ₹3.90 crore
  • Net loss: ₹22.94 lakh
  • Alevia Healthcare S.R.O.: Joint venture in Czech Republic for nutraceuticals

Manufacturing Facilities

  • Unit 1: Plot No. R-40, TTC Industrial Area, Rabale, Navi Mumbai - 400701
  • Unit 2: Plot No. 323/1, Central Hope Town, Camp Road, Selaqui, Dehradun - 248197
  • SPL Infusion Facility: Pune

Dividend

No dividend recommended for FY 2025-26.

Corporate Governance

  • Board met 8 times during the year
  • Comprises 2 Executive Directors and 3 Non-Executive Independent Directors
  • Mr. Basant Shrivastava appointed as Independent Director w.e.f. 11th September 2025
  • Mrs. Mrunmai Sarvankar's term as Independent Director expired on 19th September 2025

Auditors

  • Statutory Auditors: R.B. Gohil & Co. (appointed until 31st March 2027)
  • Secretarial Auditors: HD and Associates (appointed until 31st March 2030)
  • Unmodified audit opinions received from both auditors

CSR Activities

  • CSR obligation: ₹7.24 lakh
  • Amount spent: ₹7.24 lakh
  • Focus areas: Health, hygiene, and promotion of education

Key Operational Highlights

  • WHO-GMP certified pharmaceutical manufacturer
  • Exports to over 25 countries
  • Focus on sterile injectables, IV fluids, and oral solids
  • Expanded presence in Latin America, Central America, Middle East, and Francophone Africa
  • Strengthened R&D focus on differentiated sterile injectables and value-added nutraceuticals

Forward-Looking Statements

Management expects FY27 to be pivotal with all three growth engines (base business, SPL Infusion, and Alevia Healthcare) contributing simultaneously for the first time.

Additional Information

  • Annual Report available at www.sanjivani.co.in
  • AGM scheduled for 16th September 2026 at 11:00 AM through video conferencing
  • No material changes between year-end and report date
  • Company has adequate internal financial controls systems